Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Collyar: What's In It for Patients?

Jan

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Varsha Gandhi, PhD, on Ibrutinib

Peter Clark, MA, MD, FRCP: A Payer Perspective

Deborah Collyar: What's In It for Patients?

Can Color Vision Deficiency Impact Survival in Bladder or Colorectal Cancer

Comprehensive Multiomic Resource for HPV-Negative Head and Neck Cancers

Emergency Department Use and Unplanned Hospitalization Among Patients With Head and Neck Cancer

Reduced-Dose Intensity-Modulated Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma

Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma